Twenty-four–month event-free survival (EFS24) may predict for overall survival (OS) among patients with peripheral T cell lymphoma (PTCL), according to research published in the Journal of Clinical Oncology.1
PTCLs, which in the Western world consist primarily of anaplastic large-cell lymphoma, angioimmunoblastic T cell lymphoma, and PTCL not otherwise specified, are characterized by aggressive disease and poor response to chemotherapy. Previous study suggests that EFS is a prognostically relevant variable among patients with other lymphomas; for this study, researchers evaluated whether EFS24 predicts for overall survival in PTCL.
Of 775 patients included from 3 cohorts, only 36% reached EFS24. Among the 64% of patients who progressed within 24 months, the median OS was 4.9 months. The median among those who reached EFS24, in contrast, was not reached, with an expected 5-year OS rate of 78%.
After reaching EFS24, the 5-year relapse risk was 23%, with a median OS of 10.3 months post-relapse.
Patients 60 years and younger tended to have a longer OS after reaching EFS24; patients with ALK-negative disease were more likely reach EFS24, though they had a shorter OS thereafter.
The authors concluded that “more than one third of patients with PTCL remain in remission 2 years from diagnosis after initial chemotherapy and have encouraging OS rates, although survival remains significantly worse than the matched general population and risk of subsequent progression persists.”
- Maurer MJ, Ellin F, Srour L, et al. International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma. J Clin Oncol. 2017 Oct 26. doi: 10.1200/JCO.2017.73.8195 [Epub ahead of print]